Your browser doesn't support javascript.
loading
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J; Fisch, Michael J; Hagemeister, Fredrick B; Fanale, Michelle; Romaguera, Jorge; Pro, Barbara; Fowler, Nathan; Younes, Anas; Astrow, Alan B; Huang, Xuelin; Kwak, Larry W; Samaniego, Felipe; McLaughlin, Peter; Neelapu, Sattva S; Wang, Michael; Fayad, Luis E; Durand, Jean-Bernard; Rodriguez, M Alma.
Afiliação
  • Oki Y; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: yoki@mdanderson.org.
  • Ewer MS; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lenihan DJ; Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN.
  • Fisch MJ; Department of General Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hagemeister FB; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fanale M; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Romaguera J; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Pro B; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fowler N; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Younes A; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Astrow AB; Division of Hematology/Oncology, Department of Medicine, Maimonides Medical Center, Brooklyn, NY.
  • Huang X; Department of Biomathematics, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kwak LW; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Samaniego F; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • McLaughlin P; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Neelapu SS; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Wang M; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Fayad LE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Durand JB; Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Rodriguez MA; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
Clin Lymphoma Myeloma Leuk ; 15(3): 152-8, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25445468
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged80 Idioma: En Ano de publicação: 2015 Tipo de documento: Article